<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypogonadism in males with HIV</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypogonadism in males with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypogonadism in males with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morris Schambelan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melissa Weinberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H29753725"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypogonadism was recognized early in the HIV epidemic as being relatively common. Low serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males with HIV may be associated with a variety of manifestations including fatigue, decreased libido and erectile dysfunction, weight loss, muscle wasting, and bone loss [<a href="#rid1">1</a>].</p><p>Hypogonadism in a male refers to a decrease in one or both of the two major functions of the testes: <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> production and spermatogenesis. These abnormalities can result from disease of the testes (primary hypogonadism) or malfunction of the hypothalamus or pituitary gland (secondary hypogonadism). (See <a class="local">'Determining the etiology'</a> below.)</p><p>This topic addresses hypogonadism in males with HIV infection. General information about male hypogonadism is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism"</a> and  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism"</a>.)</p><p class="headingAnchor" id="H29753739"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The observed prevalence of hypogonadism in males with HIV decreased following the advent of potent antiretroviral therapy (ART) and adoption of early treatment.</p><p>Earlier studies of endocrine dysfunction among patients with HIV showed that 30 to 50 percent of symptomatic males had low total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels, often in association with weight loss and CD4 lymphocyte depletion, and that this finding was much more common than abnormalities in thyroid or adrenal function [<a href="#rid2">2-5</a>]. Studies conducted in the ART era suggest prevalence rates similar to those in males without HIV, although symptom burden may be higher. A systematic review including 41 studies reported a 26 percent prevalence of testosterone deficiency in males with HIV [<a href="#rid6">6</a>]. No significant difference in total testosterone levels was observed between patients with HIV and controls, though higher sex hormone-binding globulin and lower free testosterone levels were seen in persons with HIV. In another multicenter, cross-sectional study of males over 50 years of age, patients with HIV had similar prevalence of testosterone deficiency (34 percent) but higher burden of symptoms compared with the control group [<a href="#rid7">7</a>]. Other observational trials of males with HIV report hypogonadism prevalence of 6 to 10 percent [<a href="#rid8">8,9</a>]. </p><p class="headingAnchor" id="H29753767"><span class="h1">RISK FACTORS</span></p><p class="headingAnchor" id="H1034921216"><span class="h2">Age and comorbidities</span><span class="headingEndMark"> — </span>The prevalence of hypogonadism increases with advancing age regardless of HIV serostatus [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/7457.html" rel="external">"Approach to older males with low testosterone"</a>) In the general population, hypogonadism is often related to chronic disease and frailty, and these associations have also been demonstrated in those with HIV [<a href="#rid11">11</a>].</p><p>In the Cohort of HIV at-risk Aging Men's Prospective Study (CHAMPS) cross-sectional cohort study, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels were assessed in 502 men ≥49 years old with or without HIV infection [<a href="#rid12">12</a>]. Overall, 54 percent of participants had laboratory evidence of hypogonadism (defined in the study as serum testosterone &lt;300 ng/dL), but it was no more common in individuals with HIV.</p><p class="headingAnchor" id="H2125573089"><span class="h2">Obesity and insulin resistance</span><span class="headingEndMark"> — </span>A predisposing factor to hypogonadism in patients with HIV is the development of obesity and insulin resistance, especially in patients with visceral adiposity [<a href="#rid13">13,14</a>]. Some may develop these conditions as part of lipodystrophy syndrome. (See  <a class="medical medical_review" href="/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a>.)</p><p>In a cross-sectional study of 1325 men with HIV, visceral adipose tissue and body mass index (BMI) were the main predictors of low serum total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1544560148"><span class="h2">HIV-specific factors</span><span class="headingEndMark"> — </span>Serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentrations have been observed to be lower among patients with HIV who are symptomatic.</p><p>In the era before potent antiretroviral therapy (ART), gonadal function was evaluated in 70 men with HIV who were categorized as: a) asymptomatic; b) having mild symptoms and signs of HIV infection (eg, thrush, lymphadenopathy); or c) having AIDS [<a href="#rid2">2</a>]. The mean serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentrations were higher in the asymptomatic subjects compared with the other two groups. Of the hypogonadal men, 18 of 24 (75 percent) had secondary hypogonadism. Although CD4 cell counts were not available in that study, the relationship between advancing immunodeficiency and low testosterone levels was inferred by the clinical stage of disease.</p><p>In a trial including 213 ART-naïve asymptomatic men with HIV and a mean CD4 cell count of 263 cells/microL, abnormal <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels were associated with lower CD4 cell counts [<a href="#rid8">8</a>]. </p><p>In the CHAMPS study, a detectable HIV RNA level &gt;10,000 copies/mL, but not CD4 cell count levels, correlated with low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H2658412444"><span class="h2">Antiretroviral therapy</span><span class="headingEndMark"> — </span>Some small studies have demonstrated that initiation of ART can restore <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels to normal in males with hypogonadism, but others have shown no effect [<a href="#rid8">8,16</a>]. In a trial of 213 ART-naïve asymptomatic men with HIV, initiation of ART generally resulted in increased testosterone levels over the 64-week study period [<a href="#rid8">8</a>]. A cross-sectional study also demonstrated that patients on ART had higher levels of testosterone compared with those who were not on it [<a href="#rid17">17</a>].</p><p>Older studies suggested that ART, particularly protease inhibitors (PIs), may be associated with male sexual dysfunction, independent of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level [<a href="#rid18">18</a>]. In a study of 90 stable men with HIV, 53 percent reported erectile dysfunction; duration of PI use was a risk factor [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H29753774"><span class="h2">Other medications/substances</span><span class="headingEndMark"> — </span>Medications can affect sex hormones through different mechanisms. For example, systemic glucocorticoid therapy and <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a> can cause hypogonadism by suppressing the hypothalamic-pituitary-gonadal axis. <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">Ketoconazole</a>, particularly at higher doses (eg, 400 mg/day), directly inhibits steroidogenesis. Psychotropic medications can lead to hyperprolactinemia, which may result in <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> deficiency [<a href="#rid20">20</a>]. The suppression of testosterone is sometimes seen in patients on <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a> maintenance therapy; <a class="drug drug_general" data-topicid="9170" href="/d/drug information/9170.html" rel="external">buprenorphine</a> suppresses plasma testosterone to a lesser extent [<a href="#rid21">21</a>]. The chronic use of alcohol, marijuana, anabolic steroids, and opiates [<a href="#rid22">22</a>] can also impair testosterone production. (See  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a> and  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p class="headingAnchor" id="H2210812"><span class="h2">Liver disease</span><span class="headingEndMark"> — </span>Chronic hepatitis C infection has been associated with low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males with HIV, which is consistent with other studies showing a relationship between chronic liver disease and hypogonadism in the general population [<a href="#rid12">12,23</a>]. (See  <a class="medical medical_review" href="/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H29753781"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with HIV who are hypogonadal present with symptoms and signs of androgen deficiency similar to those in the general population [<a href="#rid12">12,24,25</a>]. These include fatigue, decreased libido and erectile dysfunction, weight loss, muscle wasting, and bone loss [<a href="#rid26">26</a>]. In addition, there may be loss of body hair, hot flashes, gynecomastia, anemia, and infertility in some patients. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H29753788"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2755542355"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The approach to the evaluation of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> deficiency in patients with HIV is the same as that in the general population and is discussed in detail elsewhere (see  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Diagnosis'</a>). Testing for hypogonadism is only indicated if there are suggestive symptoms or signs but not in asymptomatic individuals. Small atrophic testicles may be present on physical examination in both secondary and primary hypogonadism. (See <a class="local">'Determining the etiology'</a> below.)</p><p class="headingAnchor" id="H1800422429"><span class="h3">Checking testosterone level</span><span class="headingEndMark"> — </span>Males with HIV who have signs or symptoms suggestive of hypogonadism should undergo testing to determine the free <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level, either directly by an equilibrium dialysis assay or calculated from total testosterone, sex hormone-binding globulin (SHBG), and albumin concentrations (the calculation is typically performed by the laboratory) [<a href="#rid26">26-28</a>]. Testing should be performed 8 to 10 in the morning while fasting, and an abnormal level should be confirmed prior to treatment, as recommended in the Endocrine Society guidelines [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Free testosterone'</a> and <a class="local">'Interpretation of testosterone levels'</a> below.)</p><p>This is distinct from the general population, in whom measurement of serum total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentration (free plus protein bound fractures) is usually the initial test of choice. However, total testosterone concentrations can be misleading in males with HIV, who may have low free testosterone levels, despite normal total testosterone levels [<a href="#rid8">8,29,30</a>]. The discrepancy between total and free testosterone levels in this population may be explained by higher levels of SHBG [<a href="#rid29">29-31</a>]. </p><p>Morning levels are preferred, since <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> concentrations in males demonstrate diurnal variation, with peak levels in the morning. Measurement of serum testosterone is not advised during an acute illness when androgen levels may transiently decline. Testosterone levels may also be suppressed by food or glucose intake [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H3063121900"><span class="h3">Interpretation of testosterone levels</span><span class="headingEndMark"> — </span>The clinical suspicion of hypogonadism in males with HIV is supported by a serum free <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level below the lower limit of normal for the assay used on two separate occasions. </p><p>If total <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels were checked, repeated low values also support the diagnosis of hypogonadism. The normal range for total testosterone in adult males in most laboratories is about 300 to 800 ng/dL. </p><p>At least two measurements are recommended before confirming the diagnosis, since 30 percent of males with a low initial <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> value may normalize with repeat testing [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H2211299"><span class="h2">Determining the etiology</span><span class="headingEndMark"> — </span>Once a patient has laboratory evidence of hypogonadism, further evaluation is necessary to determine if it is secondary or primary. The first step is to check luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels (see  <a class="medical medical_review" href="/d/html/7462.html" rel="external">"Clinical features and diagnosis of male hypogonadism", section on 'Additional testing to determine etiology'</a>). In patients with HIV on antiretroviral therapy (ART), androgen deficiency is more often a consequence of secondary, rather than primary, hypogonadism, but the pathogenesis is unclear in many cases [<a href="#rid2">2,33</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hypogonadism</strong> – Normal or low levels of LH and FSH in the setting of a low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level suggest secondary hypogonadism. Such patients should be evaluated for possible reversible etiologies of gonadotropin deficiency, such as hyperprolactinemia and hemochromatosis, by checking serum prolactin and iron studies, although frequently no specific disorder is identified. We also evaluate other hormones that reflect anterior pituitary function (eg, free T4, thyroid-stimulating hormone [TSH], cortisol, insulin growth factor [IGF]-1). (See  <a class="medical medical_review" href="/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p></p><p class="bulletIndent1">We recommend performing a pituitary/hypothalamic magnetic resonance imaging (MRI) scan in patients with HIV with advanced immunodeficiency (CD4 cell count &lt;200/microL), in whom secondary hypogonadism may rarely result from opportunistic infections (eg, <em>Cryptococcus neoformans</em>, <em>Toxoplasma gondii</em>) affecting the pituitary gland or hypothalamus [<a href="#rid34">34</a>], as well as in patients who have serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> &lt;150 ng/dL, persistent hyperprolactinemia, other anterior pituitary hormone deficiency(ies), or symptoms or signs suggestive of tumor mass effect (eg, headache, visual field defect) regardless of immune status [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hypogonadism</strong> – Increased LH and FSH levels in a patient with low serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> suggest primary hypogonadism. In such cases, physical examination may show small atrophic testicles. If the primary hypogonadism is longstanding, a karyotype to exclude Klinefelter syndrome, which is the most common congenital cause of hypogonadism, is warranted. (See  <a class="medical medical_review" href="/d/html/7459.html" rel="external">"Causes of primary hypogonadism in males"</a>.)</p><p></p><p class="bulletIndent1">In patients with HIV and primary hypogonadism, a scrotal ultrasound should be performed if there is concern about an infectious process, which would be suspected in untreated patients with HIV and advanced immunodeficiency (CD4 cell count &lt;200/microL) who have testicular pain, fever, or constitutional symptoms. Testicular opportunistic infections rarely occur in the setting of viral suppression [<a href="#rid35">35</a>].</p><p></p><p class="headingAnchor" id="H3201580869"><span class="h2">Assessment for other contributing factors</span><span class="headingEndMark"> — </span>Because the clinical manifestations of hypogonadism are nonspecific, further evaluation may be warranted in patients to determine if there are other contributing factors:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreased libido or erectile dysfunction</strong> – Decreased libido or erectile dysfunction may be related to neurologic or vascular diseases, drug toxicity, or psychosexual issues. A review of medications and screening for depression are advised in this setting. (See  <a class="medical medical_review" href="/d/html/6840.html" rel="external">"Epidemiology and etiologies of male sexual dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatigue or weight loss</strong> – Fatigue or weight loss without localizing abnormalities may be the result of an opportunistic infection in patients with advanced immunodeficiency (CD4 cell count &lt;200/microL), an occult neoplasm, another underlying medical condition, or depression. A complete blood count, chemistries (including thyroid function), and inflammatory markers (eg, sedimentation rate, C-reactive protein) are advised in this setting. Additional evaluation may be warranted in patients with advanced immunodeficiency based upon presenting symptoms and signs. Age- and sex-appropriate cancer screening studies should be updated as appropriate. (See  <a class="medical medical_review" href="/d/html/2783.html" rel="external">"Approach to the adult patient with fatigue"</a> and  <a class="medical medical_review" href="/d/html/2770.html" rel="external">"Approach to the patient with unintentional weight loss"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone loss</strong> – Patients with HIV are at increased risk of bone loss. Contributing factors may include cigarette smoking, vitamin D deficiency, and history of <a class="drug drug_general" data-topicid="9895" href="/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) therapy. All patients should be screened for vitamin D deficiency, those who smoke should be provided assistance with smoking cessation, and those on TDF should be switched to a <a class="drug drug_general" data-topicid="110861" href="/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> formulation if possible. (See  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a>.)</p><p></p><p>If any of these contributing factors coexist with hypogonadism, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> supplementation may be delayed pending determination of whether there is a symptomatic and/or biochemical response to appropriate treatment for those conditions.</p><p class="headingAnchor" id="H4760064"><span class="h1">TESTOSTERONE REPLACEMENT THERAPY</span></p><p class="headingAnchor" id="H3568515893"><span class="h2">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement therapy is indicated in patients with HIV who have a low serum testosterone level (confirmed on at least two occasions in the morning without concurrent acute illness) and any of the following [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms of androgen deficiency (eg, fatigue, hot flashes/sweats, decreased libido, erectile dysfunction)</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained weight loss</p><p class="bulletIndent1"><span class="glyph">●</span>Low bone mineral density</p><p></p><p>Patients with HIV who have hypogonadal symptoms and a low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level and who are initiating antiretroviral therapy (ART) can be monitored before making a decision about whether to start supplemental testosterone, since ART may lead to increased testosterone levels [<a href="#rid8">8</a>]. It is reasonable to reevaluate such patients for hypogonadism after they have achieved normal immune function and weight.</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> therapy should not be prescribed in patients without laboratory evidence of hypogonadism. Patients who have a low testosterone level in the absence of any of the above symptoms or signs do not necessarily warrant treatment and may be monitored, but they do warrant evaluation for etiology of the hypogonadism (see <a class="local">'Determining the etiology'</a> above). If no specific cause is found, we typically reevaluate these patients both clinically and with a testosterone level in three to six months.</p><p class="headingAnchor" id="H3765398747"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Evidence regarding the effectiveness of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy in this patient population is limited. Seventy-four patients with HIV and hypogonadal symptoms were enrolled in a double-blind,<sup> </sup>placebo-controlled, six-week trial with biweekly testosterone injections (400 mg); testosterone responders and placebo recipients were then offered an additional 12 weeks of open-label testosterone therapy [<a href="#rid37">37</a>]. Among the 70 men who completed the trial, libido improved in a higher proportion of those taking testosterone compared with placebo (74 versus 19 percent). Testosterone therapy was also associated with improvement in fatigue and mood disturbance. Improvement<sup> </sup>of all parameters was maintained during subsequent open-label<sup> </sup>treatment, although no long-term follow-up was reported. </p><p>Supplemental <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> has also been effective in promoting weight gain, increased lean body mass, and higher bone mineral density in males with HIV, including those with HIV wasting syndrome [<a href="#rid6">6,38,39</a>]. In one randomized trial of 54 eugonadal men with HIV wasting syndrome, testosterone supplementation led to higher bone mineral density in the lumbar spine [<a href="#rid39">39,40</a>]. However, whether increased bone mineral density results in lower fracture risk is still unknown. </p><p class="headingAnchor" id="H106319273"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Before initiating <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy, we recommend obtaining a complete blood count, glucose, renal and hepatic function, and lipid panel. Patients should be informed of the benefits and risks of screening for prostate cancer (see  <a class="medical medical_review" href="/d/html/7567.html" rel="external">"Screening for prostate cancer"</a>) and engaged in shared decision-making regarding whether to perform a digital rectal examination and measure prostate-specific antigen (PSA) prior to testosterone supplementation. Guidelines support screening and monitoring candidates on testosterone treatment aged 55 to 69 years who have a life expectancy greater than 10 years [<a href="#rid26">26</a>]. African-American males and those with first-degree relatives with diagnosed prostate cancer are at greater risk for high-grade cancers and should start screening at age 40 years. (See  <a class="medical medical_review" href="/d/html/7567.html" rel="external">"Screening for prostate cancer", section on 'Approach to screening'</a>.) </p><p>Additional evaluation may be warranted based upon the clinical manifestations. (See <a class="local">'Assessment for other contributing factors'</a> above.)</p><p>Males with HIV ≥50 years old [<a href="#rid36">36</a>] and those with features of severe androgen deficiency or history of low trauma fracture should have bone densitometry performed [<a href="#rid26">26</a>].</p><p>The management of patients with HIV who have osteoporosis is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a>.)</p><p class="headingAnchor" id="H22157302"><span class="h2">Preparations</span><span class="headingEndMark"> — </span>As in the general population, drug selection for <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy in patients with HIV depends primarily on patient preference [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Choice of testosterone regimen'</a>.)</p><p>We generally advise one of the transdermal approaches (eg, patch, gel, or solution) as first-line treatment because of their ease of administration, lack of wide fluctuations in <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels, and fewer adverse effects compared with periodic injections  (<a class="graphic graphic_table graphicRef94118" href="/d/graphic/94118.html" rel="external">table 1</a>). The testosterone patch is applied daily over the skin of the back, thigh, or upper arm. There are now several different testosterone gel formulations, which are applied daily over a covered area of nongenital skin.</p><p>If the patient prefers an intramuscular injection, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> enanthate or testosterone cypionate may be used; a long-acting injectable agent, testosterone undecanoate in oil, is also available. Injections can be self-administered or administered in a medical setting. The dosing depends on the formulation:</p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> enanthate or cypionate, we generally start with either 200 mg every two weeks or 100 mg every week. The initial dose can then be titrated based on testosterone levels that are measured midway between injections, with the goal of achieving a level in the mid-normal range. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> undecanoate is administered as a 750 mg intramuscular injection, followed by another 750 mg injection four weeks later; it is repeated every 10 weeks thereafter [<a href="#rid26">26</a>].</p><p></p><p>There are several other <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> preparations available including oral testosterone undecanoate, subcutaneous testosterone pellets, and a nasal testosterone gel. These formulations have been less well studied than those discussed above and have not been specifically evaluated in males with HIV; thus, we do not favor these alternative approaches.</p><p class="headingAnchor" id="H7069530"><span class="h2">Duration of treatment</span><span class="headingEndMark"> — </span>For each of the indications described above, we continue <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy as long as there is clinical benefit and no significant adverse effects. If there is no effect on symptoms after three months of testosterone replacement and/or adverse effects occur, an alternative testosterone preparation can be tried or the treatment discontinued.</p><p>In clinical practice, sometimes patients presenting for care are on <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy for unclear indications. Checking luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in a patient receiving exogenous testosterone is not useful since gonadotropins will be suppressed. Because there are no evidence-based guidelines regarding whether to continue testosterone in this setting, the decision must be individualized, taking into consideration the risks and benefits of treatment as well as patient preference. If testosterone is discontinued in these patients, it may take months for endogenous gonadal function to resume and may not be well tolerated.</p><p class="headingAnchor" id="H2211589"><span class="h2">Adverse events</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement therapy can cause acne and emotional lability in some patients. With chronic administration, patients can also develop erythrocytosis and testicular atrophy. Preexisting sleep apnea may also worsen.</p><p>The patch or gel methods can be associated with skin irritation, and injections may cause injection-site reactions. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Potential adverse effects'</a>.)</p><p>There are no important interactions with any antiretroviral drugs.</p><p class="headingAnchor" id="H12617787"><span class="h2">Contraindications and cautions</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> treatment has been associated with clinical benefits in males with hypogonadism, many questions remain unanswered including the long-term effects of suppression of the hypothalamic-pituitary-gonadal axis, as well as the possibility of promoting or unmasking malignancy of the prostate [<a href="#rid41">41</a>] and increasing the risk of cardiovascular disease [<a href="#rid42">42</a>] and venous thromboembolism [<a href="#rid43">43</a>]. Patients should be counseled regarding these uncertainties before initiating treatment.</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> should not be initiated in patients with any of the following [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>History of metastatic prostate or breast cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Unevaluated prostate nodule or induration</p><p class="bulletIndent1"><span class="glyph">●</span>PSA &gt;4 ng/mL or &gt;3 ng/mL in males at high risk for prostate cancer (eg, African Americans or males with first-degree relatives with prostate cancer) without urologic evaluation</p><p class="bulletIndent1"><span class="glyph">●</span>Hematocrit &gt;48 percent (&gt;50 percent for males living at high altitude)</p><p class="bulletIndent1"><span class="glyph">●</span>Severe lower urinary tract symptoms </p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled or poorly controlled heart failure </p><p class="bulletIndent1"><span class="glyph">●</span>Desire for fertility in the next 6 to 12 months </p><p></p><p>Exogenous <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> may cause suppression of spermatogenesis and should not be given to men who desire fertility in the near term.</p><p><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> should be used with caution in patients who have thrombophilia, underlying cardiovascular disease, or multiple cardiovascular risk factors. This is especially relevant for persons with HIV because cardiovascular risk factors and comorbidities are more prevalent in this population [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Venous thromboembolism'</a> and  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Cardiovascular risks'</a>.)</p><p>Patients who use topical <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> gel should be made aware of the risk of unintentional transfer of drug by skin contact, particularly to female partners or children, who may become virilized as a result. Secondary exposure can be avoided by washing hands after application, covering the application site, and allowing the gel to completely dry before any direct skin-to-skin contact (see  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Secondary exposure: Minimal risk with precautions'</a>). The relative advantages and disadvantages of the different formulations are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Choice of testosterone regimen'</a>.)</p><p class="headingAnchor" id="H2211520"><span class="h2">Monitoring patients</span><span class="headingEndMark"> — </span>Clinical effectiveness, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels, and adverse drug effects should be monitored at three to six months, 12 months, and annually thereafter (see  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Monitoring'</a>). The target goal should be attainment of morning serum testosterone levels in the mid-normal range. Patients receiving testosterone injections should have levels checked midway between injections.</p><p>The hematocrit should be checked at baseline, after three to six months of therapy, and annually thereafter, since <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy can be associated with erythrocytosis. Identification and management of erythrocytosis in the setting of testosterone therapy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Erythrocytosis'</a>.)</p><p>The patient should be counseled regarding the risks and benefits of prostate cancer monitoring in order to determine a plan consistent with his values and preferences. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7461.html" rel="external">"Testosterone treatment of male hypogonadism", section on 'Prostate cancer'</a>.)</p><p>We suggest repeating bone densitometry after one to two years of <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy in hypogonadal males with osteoporosis or low-trauma fracture [<a href="#rid26">26</a>]. If it is stable or improved, less frequent monitoring may be performed. (See  <a class="medical medical_review" href="/d/html/3738.html" rel="external">"Bone and calcium disorders in patients with HIV"</a>.)</p><p class="headingAnchor" id="H2123723158"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111628.html" rel="external">"Society guideline links: Primary care of adults with HIV"</a>.)</p><p class="headingAnchor" id="H29753935"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hypogonadism was recognized as being relatively common early in the HIV epidemic. Low serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels in males with HIV may be associated with a variety of manifestations including fatigue, decreased libido and erectile dysfunction, weight loss, muscle wasting, and bone loss. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of treatment for hypogonadism in males with HIV has been observed to be lower (about 10 percent) since the advent of effective antiretroviral therapy (ART) and its earlier initiation in their care. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for hypogonadism in males with HIV include increasing age, symptomatic infection, use of certain drugs (eg, systemic glucocorticoids, opiates, <a class="drug drug_general" data-topicid="9603" href="/d/drug information/9603.html" rel="external">megestrol acetate</a>, <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>), and chronic hepatitis C infection. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In males with HIV who have signs or symptoms suggestive of hypogonadism, the diagnosis is supported by a low serum free <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level, either calculated or measured directly by equilibrium dialysis and confirmed on repeat testing. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Testing should be performed 8 to 10 in the morning while fasting. Measurement of serum <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> is not advised during an acute illness when androgen levels may transiently decline. (See <a class="local">'Checking testosterone level'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Once a patient has laboratory evidence of hypogonadism, further evaluation is necessary to determine if it is primary or secondary. Normal or low levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in the setting of a low <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> level suggest secondary hypogonadism. Increased LH and FSH levels in a patient with low serum testosterone suggest primary hypogonadism. Additional testing or imaging may be warranted to establish the specific etiology. (See <a class="local">'Determining the etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">Testosterone</a> replacement therapy is indicated in patients with HIV who have a consistently low serum free testosterone level and symptoms of androgen deficiency (eg, fatigue, hot flashes/sweats, decreased libido, erectile dysfunction), unexplained weight loss, or low bone mineral density. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Before initiating <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> replacement therapy, we recommend obtaining a complete blood count, glucose, renal and hepatic function, and a lipid panel. For males who choose prostate cancer monitoring after discussion of the associated risks and benefits, a prostate-specific antigen should be checked and a digital rectal examination performed. Additional evaluation may be warranted based upon presenting manifestations. (See <a class="local">'Pretreatment evaluation'</a> above and <a class="local">'Assessment for other contributing factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally use one of the transdermal approaches (eg, patch or gel) as first-line treatment because of their ease of administration, lack of wide fluctuations in <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels, and fewer adverse effects compared with injections  (<a class="graphic graphic_table graphicRef94118" href="/d/graphic/94118.html" rel="external">table 1</a>).The testosterone patch is applied daily over the skin of the back, thigh, or upper arm. There are now several different testosterone gel formulations, which are applied daily over a covered area of nongenital skin. (See <a class="local">'Preparations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Many questions remain unanswered regarding the long-term clinical benefits versus the possible prostate, cardiovascular, and thromboembolic risks with <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> treatment. These issues should be discussed with patients prior to initiating therapy. (See <a class="local">'Contraindications and cautions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical effectiveness, <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> levels, and adverse drug effects should be monitored at three to six months, 12 months, and annually thereafter. The target goal should be attainment of serum testosterone levels obtained in the morning in the mid-normal range. (See <a class="local">'Monitoring patients'</a> above.)</p><p></p><p class="headingAnchor" id="H2923054904"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wanke CA, Silva M, Knox TA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803.</a></li><li><a class="nounderline abstract_t">Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988; 84:611.</a></li><li><a class="nounderline abstract_t">Raffi F, Brisseau JM, Planchon B, et al. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS 1991; 5:729.</a></li><li><a class="nounderline abstract_t">Christeff N, Gharakhanian S, Thobie N, et al. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr 1992; 5:841.</a></li><li><a class="nounderline abstract_t">Dobs AS, Few WL 3rd, Blackman MR, et al. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996; 81:4108.</a></li><li><a class="nounderline abstract_t">Santi D, Spaggiari G, Vena W, et al. The Prevalence of Hypogonadism and the Effectiveness of Androgen Administration on Body Composition in HIV-Infected Men: A Meta-Analysis. Cells 2021; 10.</a></li><li><a class="nounderline abstract_t">Postel N, Wolf E, Balogh A, et al. Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection. Exp Clin Endocrinol Diabetes 2021; 129:798.</a></li><li><a class="nounderline abstract_t">Dubé MP, Parker RA, Mulligan K, et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007; 45:120.</a></li><li><a class="nounderline abstract_t">Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS 2015; 29:77.</a></li><li><a class="nounderline abstract_t">Slama L, Jacobson LP, Li X, et al. Longitudinal Changes Over 10 Years in Free Testosterone Among HIV-Infected and HIV-Uninfected Men. J Acquir Immune Defic Syndr 2016; 71:57.</a></li><li><a class="nounderline abstract_t">Rochira V, Diazzi C, Santi D, et al. Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology 2015; 3:298.</a></li><li><a class="nounderline abstract_t">Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41:1794.</a></li><li><a class="nounderline abstract_t">Grossmann M, Gianatti EJ, Zajac JD. Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17:247.</a></li><li><a class="nounderline abstract_t">Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009; 5:673.</a></li><li><a class="nounderline abstract_t">Rochira V, Zirilli L, Orlando G, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 2011; 6:e28512.</a></li><li><a class="nounderline abstract_t">Wunder DM, Bersinger NA, Fux CA, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007; 12:261.</a></li><li><a class="nounderline abstract_t">Collazos J, Martinez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS 2002; 16:934.</a></li><li><a class="nounderline abstract_t">Collazos J. Sexual dysfunction in the highly active antiretroviral therapy era. AIDS Rev 2007; 9:237.</a></li><li><a class="nounderline abstract_t">Moreno-Pérez O, Escoín C, Serna-Candel C, et al. Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. AIDS 2010; 24:255.</a></li><li><a class="nounderline abstract_t">Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65:1607.</a></li><li><a class="nounderline abstract_t">Bliesener N, Albrecht S, Schwager A, et al. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 2005; 90:203.</a></li><li><a class="nounderline abstract_t">Cooper OB, Brown TT, Dobs AS. Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clin Infect Dis 2003; 37 Suppl 2:S132.</a></li><li><a class="nounderline abstract_t">Bannister P, Handley T, Chapman C, Losowsky MS. Hypogonadism in chronic liver disease: impaired release of luteinising hormone. Br Med J (Clin Res Ed) 1986; 293:1191.</a></li><li><a class="nounderline abstract_t">Dobs A. Role of testosterone in maintaining lean body mass and bone density in HIV-infected patients. Int J Impot Res 2003; 15 Suppl 4:S21.</a></li><li><a class="nounderline abstract_t">Tindall B, Forde S, Goldstein D, et al. Sexual dysfunction in advanced HIV disease. AIDS Care 1994; 6:105.</a></li><li><a class="nounderline abstract_t">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:1715.</a></li><li><a class="nounderline abstract_t">de Ronde W, van der Schouw YT, Pols HA, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem 2006; 52:1777.</a></li><li><a class="nounderline abstract_t">Rosner W, Auchus RJ, Azziz R, et al. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92:405.</a></li><li><a class="nounderline abstract_t">Rietschel P, Corcoran C, Stanley T, et al. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000; 31:1240.</a></li><li><a class="nounderline abstract_t">Pezzaioli LC, Quiros-Roldan E, Paghera S, et al. The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience. Infection 2021; 49:295.</a></li><li><a class="nounderline abstract_t">Martin ME, Benassayag C, Amiel C, et al. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+patients. J Endocrinol Invest 1992; 15:597.</a></li><li><a class="nounderline abstract_t">Caronia LM, Dwyer AA, Hayden D, et al. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf) 2013; 78:291.</a></li><li><a class="nounderline abstract_t">Arver S, Sinha-Hikim I, Beall G, et al. Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. J Androl 1999; 20:611.</a></li><li><a class="nounderline abstract_t">Etzel JV, Brocavich JM, Torre M. Endocrine complications associated with human immunodeficiency virus infection. Clin Pharm 1992; 11:705.</a></li><li><a class="nounderline abstract_t">Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin North Am 2003; 17:889.</a></li><li><a class="nounderline abstract_t">Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:1.</a></li><li><a class="nounderline abstract_t">Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57:141.</a></li><li><a class="nounderline abstract_t">Kong A, Edmonds P. Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. Lancet Infect Dis 2002; 2:692.</a></li><li><a class="nounderline abstract_t">Grant PM, Li X, Jacobson LP, et al. Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men. AIDS Res Hum Retroviruses 2019; 35:75.</a></li><li><a class="nounderline abstract_t">Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001; 86:2020.</a></li><li><a class="nounderline abstract_t">Abrams D. Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy. AIDS Read 2001; 11:149.</a></li><li class="breakAll">Endocrine Society. Endocrine Society Calls for Large-Scale Studies to Evaluate Testosterone Therapy Risks. https://www.endocrine.org/news-room/press-release-archives/2014/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks (Accessed on January 23, 2015).</li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due (Accessed on February 28, 2022).</li><li><a class="nounderline abstract_t">Grant JK, Loyd Q, Martinez C. Testosterone, HIV, and cardiovascular disease risk. Cardiovasc Endocrinol Metab 2021; 10:72.</a></li></ol></div><div id="topicVersionRevision">Topic 13969 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017833" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3348269" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Endocrine disorders in men infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883545" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endocrine function in 98 HIV-infected patients: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1387684" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence for changes in adrenal and testicular steroids during HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923868" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Serum hormones in men with human immunodeficiency virus-associated wasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34440836" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Prevalence of Hypogonadism and the Effectiveness of Androgen Administration on Body Composition in HIV-Infected Men: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33477181" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554712" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25387318" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26761271" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Longitudinal Changes Over 10 Years in Free Testosterone Among HIV-Infected and HIV-Uninfected Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25704864" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288406" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Androgen levels in older men who have or who are at risk of acquiring HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20418720" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Testosterone and type 2 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19859074" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Testosterone deficiency, insulin resistance and the metabolic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22174826" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Premature decline of serum total testosterone in HIV-infected men in the HAART-era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503668" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11919500" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219367" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sexual dysfunction in the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915446" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641865" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483091" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12942387" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3096427" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hypogonadism in chronic liver disease: impaired release of luteinising hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12934047" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Role of testosterone in maintaining lean body mass and bone density in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8186272" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Sexual dysfunction in advanced HIV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562364" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16793931" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17090633" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073758" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289905" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The importance of SHBG and calculated free testosterone for the diagnosis of symptomatic hypogonadism in HIV-infected men: a single-centre real-life experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430842" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22804876" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520573" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1511543" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endocrine complications associated with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12852661" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Non-AIDS-defining cancer in HIV-infected people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24343580" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665616" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409050" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280921" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of Testosterone Use on Bone Mineral Density in HIV-Infected Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344201" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004352" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004352" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17004352" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of androgens in patients who have HIV/AIDS: what we know about the effect of androgens on wasting and lipodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34124602" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Testosterone, HIV, and cardiovascular disease risk.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
